Talk:List of therapeutic monoclonal antibodies

Untitled
Subpages: Hoaxes

I've seen someone put Campath in my list, or efalizumab will block the T cell migration. --BlakeCS 07:20, 26 January 2007 (UTC)

Purpose
Let's see if I can expand this whole list as I can. Right? --Blake3522 14:11, 8 July 2007 (UTC)
 * OK. I can get this higher than 10KB. --Blake3522 06:23, 15 July 2007 (UTC)

Deleted
All hoaxes were deleted per Articles for deletion/Ananeuzumab. --202.67.104.55 (talk) 12:47, 25 December 2007 (UTC)

Hoax warning
Unfortunately, Blake3522 and BlakeCL created dozens and dozens of bogus stubs. It may well be that not all have been deleted, or that some redlinks here relate to bogus articles. Someone knowledgeable needs to check.--Scott MacDonald (talk) 23:42, 4 October 2008 (UTC)
 * As mentioned in the section above, or in the subpage. --58.178.193.122 (talk) 06:19, 10 October 2008 (UTC)
 * As of January 2010, all redlinks in this list have been checked and sourced. --ἀνυπόδητος (talk) 13:33, 15 January 2010 (UTC)

Proposal to create additional column "Action"
This column would be placed after "Target" (before "Use") and there would likely be 2 or 3 target types, possibly receptor inhibitor, mab inhibitor, or mab analogue. (I don't know this area well but I think this extra column would be really informative). Mangofast (talk) 11:08, 15 March 2016 (UTC)

Rules for new entries
Some antibodies appear as separate entries, even though they correspond to the same compound ( Lambrolizumab, Pembrolizumab ) and the linked wikipedia page refers to them as being the same. On the other hand for historic reasons they may be considered separate products. Presently it is not clear under which conditions separate entries should be kept. Tsttsttsttst (talk) 19:30, 21 March 2017 (UTC)
 * I'd say they are synonyms of the same substance, so they shouldn't have separate entries in the list just as they don't have separate articles. I have removed the lambrolizumab row. Thanks for catching this. --ἀνυπόδητος (talk) 07:44, 22 March 2017 (UTC)